Markers of coagulation and inflammation and adverse events in patients with active cancer and atherosclerosis: common features and differences

Introduction. Thrombotic complications (TC) in different vascular systems dictate the fate of high-risk patients. In cardiological practice, patients with advanced atherosclerotic disease (MFA) represent most vulnerable group. Malignant neoplasm (MN) is one significant risk factors for developing TCs, especially context antineoplastic therapy. The presence differences mechanisms thrombogenesis malignant neoplasms and atherosclerosis determines appropriateness a comparative study markers coagulation activation endothelial damage order to identify common features specific each pathology. Aim. To examine growth active cancer disease, their Materials methods. A total 22 MN (Group 1) 58 MFA 2) were enrolled study. assessed biomarkers included: von Willebrand factor (VWF), D-dimer, differentiation factor-15 (GDF-15) (VEGF-A). Results. Patients had an increased likelihood progression within 6 months at D-dimer level > 1121 ng/mL (OR = 10.5; 95% CI 1.4–81.0, p 0.014) or VWF 189% 10.5, 1.36–81.0, 0.014); death two years follow-up 7.0; 0.97–50.57, 0.04), 203% 10, 5, 1.36–81.06, 0.014). MFA, prognosis determining events one-year was determined by levels 157% 9.2, 1.02–82.8, 0.048) GDF-15 1548 pg/ml 5.7; 1.09–29.5, 0.04). Conclusions. Endothelial are more pronounced than MFA. neoplasms, outcomes associated levels, – levels.